肿瘤免疫：生物创新【研报】

pengxuleo

+ U) J5 `. P8 r2 `* W2 E( g
) r1 F+ i% U5 W8 O' I9 d' V目录
2 d. ]5 ~+ |8 X免疫治疗引领肿瘤治疗新模式 ...................................................................................................... 4
! k; `, i! I8 ?9 \4 X抗癌领域新突破 .................................................................................................................. 4% h" ~' l, [4 g- u- i6 i
600 亿美元市场空间 ............................................................................................................ 4
4 Y: z8 P3 f& U: b8 J免疫检查点的突破——PD-1 ....................................................................................................... 5- w+ a4 s3 @1 ^  H8 c: `* |
PD-1 单抗——肿瘤免疫治疗的明星 .......................................................................................... 5/ ~( D/ c$ j" j/ Z
PD-1 重磅产品频出 ............................................................................................................. 5
3 P$ h8 h5 f& U; {在研PD-1 单抗全面开花 ....................................................................................................... 6; u8 F* S7 r, S2 F/ t
PD-1 临床试验数据——适应人群广泛，效果显著 .......................................................................... 7# a! _& i  ^; {# E% O
PD-1 以优秀的临床表现快速斩获非小细胞肺癌适应症 .................................................................... 9! Q$ ^" q( N/ N/ ?* R; s9 X# _: s
PD-1 联用——免疫鸡尾酒疗法引爆行业增长点 ............................................................................ 9
9 O7 w: F. t3 M! B, s' MPD-1 市场前景广阔 ........................................................................................................... 10
% J9 H% z" z* `: b2 V免疫治疗热门靶点——PD-L1 ................................................................................................... 19
6 P7 W1 g: m0 ?7 a1 sPD-L1 单抗免疫疗法原理 .................................................................................................... 19
5 |; z! h+ D& k: [$ f& WPD-L1 单抗在研情况 .......................................................................................................... 19
2 K- U3 A. z; a" e8 `, ^PD-L1 联用——多靶点治疗新选择 ......................................................................................... 19  P7 f5 L1 k1 C! R2 o8 b
PD-L1 未来市场 ............................................................................................................... 20
. A1 Q' P+ }9 r6 j/ P' N免疫治疗另一靶点——CTLA-4 .................................................................................................. 21
3 d. ?( h( r9 p9 I2 k2 wCTLA-4 单抗免疫疗法原理 ................................................................................................... 21- R' @8 K% J; r6 R1 Z5 l
CTLA-4 单抗已上市产品 ..................................................................................................... 21+ B% O7 v8 \1 w+ u3 y
CTLA-4 在研产品.............................................................................................................. 22
5 |. j7 Q# a- ^3 ?: ACTLA-4 的未来，联合用药是出路 .......................................................................................... 234 {. K8 z9 @( L  `# _
相关公司简介 ........................................................................................................................ 246 V: u# E7 @1 d1 U& u' @  ]1 g; e- y- ]
君实生物 ........................................................................................................................ 24
. I' l) n3 G- b- |7 W* a: Z恒瑞医药（确信买入评级） .................................................................................................. 25! e" c+ c4 Z4 C8 H: ^
百时美施贵宝（BMS） ....................................................................................................... 26
. ~# T+ g! R3 A6 y/ j* X默克（Merck） ................................................................................................................ 27" v" M3 ?4 Y, S8 |( S
2 W8 Y! l2 m, ?: `0 G6 l/ R2 r# y
/ h8 e% u5 Y' _4 v2 a: S2 F: Y
[hide][/hide]

ljf452719

好好学习

wzs1985

这两年最火的东西，谢谢了啊

11yzhangy8

好东西。看看

h3636

看看

zhengjianwei521

sky-sky

谢谢分享5 o, C* g# E' r) H4 e4 x

小云龙

学习

hameln

看看

xy7500

了解, X: I! q5 j6 Q; H
一下